88
Participants
Start Date
April 30, 2008
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2012
OS (oxalipaltin+S-1)
Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
XELOX (oxalipaltin+capecitabine)
Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Hallym University Medical Center, Anyang
Collaborators (1)
Sanofi
INDUSTRY
Hallym University Medical Center
OTHER